9. Research Grants


NHLBI Research Grants by Funding Mechanism: Fiscal Year 2011

Research Project Grants (RPGs) Number of
Grants
Total Cost
(Dollars in Thousands)
Percent of
Total NHLBI
Research
Grant Dollars
Research Project Grants (Excluding Small Business RPGs)      
Regular Research Grants (R01) 2,943 $1,355,916 59.25%
Program Project Grants (P01) 153 321,179 14.03
Cooperative Agreements (U01) 156 180,217 7.87
Explorative Developmental Grant (R21) 316 68,722 3.00
Method to Extend Research in Time (R37) 71 30,775 1.34
Exploratory/Developmental Grants Phase II (R33) 3 2,289 0.10
Clinical Trial Planning Grant (R34) 12 4,646 0.20
Clinical Planning Grant Cooperative Agreement (U34) 2 1,573 0.07
Academic Research Enhancement Award (R15) 9 3,547 0.15
NIH Director's New Innovator's Award (DP2) 2 4,928 0.22
Research Transition Award (R00) 75 18,606 0.81
Cooperative Agreements (U19) 3 6,513 0.28
Small Research Grants (R03) 9 693 0.03
Linked Research Grant (RL1) 59 0.00
NIH Director's Pioneer Award (DP1) 3 2,255 0.10
Exploratory/Developmental Cooperative Agreements Phase I (UH2) 2 988 0.04
Multi-Component Research Project Cooperative Agreements (UM1) 2,079 0.09
Subtotal, Research Project Grants (Excluding Small Business RPGs) 3,759 2,004,985 88.00
Small Business Research Project Grants      
Small Business Technology Transfer (STTR Phase I) (R41) 15 3,396 0.15
Small Business Technology Transfer (STTR Phase II) (R42) 11 5,608 0.25
Small Business Innovation Research (SBIR Phase I) (R43) 67 16,973 0.74
Small Business Innovation Research (SBIR Phase II) (R44) 70 48,958 2.14
Subtotal, Small Business Research Project Grants 163 74,935 3.26
Subtotal, Research Project Grants 3,922 2,079,920 91.26
Research Centers Grants
Centers of Research Programs (P50) 30 34,366 1.50
Sickle Cell Centers (U54) 13 5,901 0.26
Centers for AIDS Research (P30) 3,334 0.15
Specialized Centers (Cooperative Agreements) (U54) 1,265 0.06
National Swine Research and Resource Center (U42) 1,448 0.06
Exploratory Grants (P20) 12 8,593 0.38
Center Core Grants (P30) 5 1,024 0.04
Subtotal, Research Centers Grants 60 55,931 2.44
Research Career Programs      
Mentored Research Scientist Development Award for Minority Faculty (K01) 45 5,860 0.26
Minority Institution Faculty Mentored Research Scientist Development Award (K01) 5 668 0.03
Mentored Scientist Development Award in Research Ethics (K01) 126 0.01
Independent Scientist Award (K02) 21 2,076 0.09
Pediatric Transfusion Medicine Academic Award (K07) 4 486 0.02
Innovators in Hemoglobinopathies Care Career Development Award (K07) 2 574 0.03
Clinical Investigator Development Award (K08) 210 27,166 1.19
Research Career Development Program in Vascular Medicine (K12) 3 2,499 0.11
Clinical Research Career Development Programs in Emergency Medicine (K12) 6 1,186 0.05
Career Enhancement Award for Stem Cell Research (K18) 5 789 0.03
Career Transition Award (K22) 3 699 0.03
Mentored Patient-Oriented Research Career Development Award (K23) 170 23,871 1.04
Midcareer Investigator Award in Patient-Oriented Research (K24) 34 5,851 0.26
Mentored Quantitative Research Career Development Award (K25) 15 2,110 0.09
Career Transition Award (K99) 47 5,129 0.22
Subtotal, Research Career Programs 570 79,090 3.46
Other Research Grants      
Cooperative Clinical Research (U10, R10) 50 44,705 1.95
Minority Biomedical Research Support (S06, SC1, SC2) 13 2,883 0.13
Other (D43, R13, R18, R24, R25, T15, U24, UH1) 115 26,094 1.14
Subtotal, Other Research Grants 178 73,682 3.22
Total, NHLBI Research Grants 4,730 $2,288,623 100%


NHLBI Total Research Grants by Category

NHLBI Total Research Grants by Category
Text-only with data points

NHLBI Research Project Grant, Research Centers Grants, and Other Research Grant Obligations: Fiscal Years 2001–2011

NHLBI Research Project Grant, Research Centers Grant, and Other Research Grant Obligations
Text-only with data points are represented in the table below.

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.
**Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Research Project Grants, Research Centers Grants, and Other Research Grant Obligations: Fiscal Years 2001–2011

Dollars (Thousands)

 

FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011
Research Project Grants* $1,580,751 $1,779,573 $1,920,201 $2,003,769 $2,042,050 $2,011,049 $1,986,692 $1,983,633 $2,039,861 $2,108,524 $2,079,920
Research Centers Grants 127,232 128,161 138,941 140,600 151,495 141,086 141,034 107,393 90,152 72,566 55,931
Other Research Grants** 88,958 98,460 113,172 112,785 116,713 123,802 135,284 125,942 131,001 129,245 152,772
Total $1,796,941 $2,006,194 $2,172,314 $2,257,154 $2,310,258 $2,275,937 $2,263,010 $2,216,968 $2,261,014 $2,310,335 $2,288,623

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.
** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Competing Research Project Grant Applications:* Fiscal Years 2001–2011

Number Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 2001-2011, Number Reviewed and Awarded
Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded

 

FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 2011
Applications Reviewed 2,895 3,064 3,098 3,548 3,865 4,412 4,504 4,492 4,373 4,528 4,931
Applications Awarded 1,033 1,018 1,064 1,034 909 871 943 997 968 903 856
Percent Funded (Success Rate) 35.7 33.2 34.3 29.1 23.5 19.7 20.9 22.2 22.1 19.9 17.4

*  Includes R01, U01, P01, R03, R15, R21, R29, and R37; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

Percent of Reviewed Applications Funded (Success Rate)

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 2001-2011, Percent of Reviewed Applications Funded (Success Rate)
Text-only with data points are represented in the table above.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 2001–2011

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 2001-2011
Text-only with data points are represented in the table below.

* Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
**Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 2001–2011

Dollars (Millions)

 

FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011
Investigator-Initiated* $1,446.2 $1,584.9 $1,681.9 $1,773.4 $1,822.9 $1,802.1 $1,774.8 $1,820.8 $1,850.1 $1,950.9 $1,921.9
Institute-Initiated** 350.7 421.3 490.4 483.8 487.3 473.8 488.2 396.1 410.9 359.5 366.7
Total $1,796.9 $2,006.2 $2,172.3 $2,257.2 $2,310.2 $2,275.9 $2,263.0 $2,216.9 $2,261.0 $2,310.4 $2,288.6

* Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Research Project Grants:*  Amount Funded by Type of Award, Fiscal Years 2001–2011

Dollars (Millions)

 

FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011
Competing                      
  New Competing $   280.0 $   291.2 $   285.5 $   290.5 $   270.0 $   242.9 $   330.9 $   314.2 $ 340.2 $ 330.5 $ 353.1
  Renewal Competing 143.9 143.9 177.2 185.5 176.1 168.3 169.4 196.9 172.6 171.6 131.6
  Competing
  Supplements
0.4 2.3 1 1.3 1.7 0.4 1.7 0.3 0.3
Subtotal, Competing 424.3 437.4 463.7 477.3 447.8 411.6 500.3 512.8 513.1 501.8 484.7
Noncompeting                      
Subtotal, Noncompeting 1,101.5 1,281.3 1,390.3 1,454.9 1,520.0 1,527.0 1,486.4 1,470.8 1,526.8 1,606.7 1,595.2
Total, Competing and Noncompeting $1,525.8 $1,718.7 $1,854.0 $1,932.2 $1,967.8 $1,938.6 $1,986.7 $1,983.6 $2,039.9 $2,108.5 $2,079.9

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

Facility and Administrative (F&A) Costs of NHLBI Research Project Grants:* Fiscal Years 2001–2011

Dollars (Thousands)

Fiscal Year Direct Cost F&A Cost Total Cost F&A Cost as a
Percent of Direct Cost
2001 1,045,144 480,673 1,525,817 46.0
2002 1,182,408 536,324 1,718,732 45.4
2003 1,276,819 577,131 1,853,950 45.2
2004 1,329,106 603,133 1,932,239 45.4
2005 1,355,803 612,007 1,967,810 45.1
2006 1,334,406 604,183 1,938,589 45.3
2007 1,378,134 608,558 1,986,692 44.2
2008 1,376,276 607,357 1,983,633 44.1
2009 1,410,033 629,828 2,039,861 44.7
2010 1,459,211 649,313 2,108,524 44.5
2011 1,429,935 649,985 2,079,920 45.5

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 2001–2011

NHLBI Research Project Grants*:  Average Costs, Fiscal Years 2001-2011
Text-only with data points are represented in the table below.

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 2001–2011

Dollars (Thousands)

 

FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011
Noncompeting $390.7 $418.8 $444.4 $458.7 $490.6 $503.9 $510.3 $512.4 $509.8 $532.2 $538.6
Competing 410.8 409.1 406.7 419.7 459.9 458.1 477.8 462.0 478.2 497.9 504.9
Total $396.1 $416.2 $433.8 $447.9 $484.8 $492.8 $501.7 $501.8 $501.4 $523.6 $530.3

*Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

NHLBI Cooperative Agreements (U01, U10, U19) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator's spe­cific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

 

Total Obligations Prior to FY 2011 Total FY 2011 Obligations Total Obligations to Date
Heart and Vascular Diseases      
ARIC Neurocognitive Study (ARIC-NCS) $4,024,211 $5,132,469 $9,156,680
Cardiovascular Cell Therapy Research Network 24,419,327 3,800,000 28,219,327
Cardiovascular Inflammation Reduction Trial 1,375,726 1,375,726
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) 25,827,224 3,029,201 28,856,425
Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial 5,985,643 3,032,875 9,018,518
Center for Cardiovascular Outcomes Research 5,203,594 4,964,931 10,168,525
Childhood Obesity Prevention and Treatment Research (COPTR) 4,058,435 3,986,427 8,044,862
Claudication Exercise Versus Endoluminal Revascularization (CLEVER) 7,647,416 1,371,307 9,018,723
Clinical Research Consortium To Improve Resuscitation Outcomes 46,447,452 9,455,378 55,902,830
Consortium of Hospitals Advancing Research on Tobacco (CHART) 3,321,649 3,505,096 6,826,745
Cross Organ Mechanism-Associated Phenotypes For Genetic Analysis of H, L, B, and S Diseases 4,275,465 4,275,465
Diabetes Prevention Program Outcomes Study—Phase II 2,200,000 1,100,000 3,300,000
Dynamic Evaluation of Percutaneous Coronary Intervention 8,413,711 742,170 9,155,881
Early Adult Reduction of Weight Through LifestYle Intervention (EARLY) Trials* 10,519,703 6,123,513 16,643,216
Genetics of Coronary Artery Disease in Alaskan Natives (GOCADAN) 17,504,059 51,881 17,555,940
Heart Failure Clinical Research Network 37,108,888 7,651,786 44,760,674
ISCHEMIA Trial (International Study of Comparative Effectiveness With Medical Invasive Approaches) 6,671,629 6,671,629
Look AHEAD: Action for Health in Diabetes 8,000,000 4,000,000 12,000,000
Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine 25,978,806 5,459,597 31,438,403
Next Generation Genetic Association Studies 5,855,804 5,855,804
NHLBI Cardiac Development Consortium 8,239,641 7,037,111 15,276,752
NHLBI Pediatric Cardiac Genomics Consortium 5,143,441 3,814,314 8,957,755
NHLBI Pediatric Translational Consortium Administrative Coordinating Center 10,453,976 10,453,976
NHLBI Progenitor Cell Biology Consortium Research Hubs 46,788,094 22,514,886 69,302,980
Obesity Related Behavioral Intervention Trials (ORBIT)** 10,987,451 4,297,228 15,284,679
Pediatric Heart Network 63,348,873 12,827,177 76,176,050
Pharmacogenetics Research Network 74,421,336 6,532,424 80,953,760
Ranolazine in Implantable Defibrillators (RAID) Trial 2,279,794 2,279,794
Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II) 4,419,188 366,525 4,785,713
Strong Heart Study 73,879,041 2,144,794 76,023,835
Surgical Treatment for Ischemic Heart Failure (STICH) 40,041,062 352,198 40,393,260
Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials 5,993,723 4,401,772 10,395,495
Subtotal, Heart and Vascular Diseases 582,655,738 145,873,684 728,529,422
Lung Diseases      
Asthma Networks (AsthmaNet) 23,800,000 15,500,000 39,300,000
COPD Clinical Research Network 46,330,386 2,600,000 48,930,386
Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT) 2,685,460 2,685,460
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) 2,244,874 628,241 2,873,115
Microbiome of the Lung and Respiratory Tract in HIV-Infected and in HIV-Uninfected Controls 10,743,005 5,324,656 16,067,661
Novel Therapies for Lung Diseases—Phase II 7,593,739 12,843,238 20,436,977
Pharmacogenetics of Asthma Treatment 28,998,338 1,957,381 30,955,719
Prematurity and Respiratory Outcomes Program (PROP) 1,597,280 4,066,948 5,664,228
Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk 500,000 3,298,000 3,798,000
Randomized Trial of Antenatal Late Preterm Steroids (ALPS) 2,133,947 2,137,414 4,271,361
Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma 4,975,916 2,469,339 7,445,255
Sedation Management in Pediatric Patients With Acute Respiratory Failure 7,779,116 2,181,199 9,960,315
Severe Asthma Research Program 5,159,933 5,159,933
Study of Asthma and Nasal Steroids (STAN) 1,449,536 724,884 2,174,420
Study of Soy Isoflavones in Asthma (SOYA) 1,417,854 688,673 2,106,527
Trial of Late Surfactant (TOLSURF) To Prevent Bronchopulmonary Dysplasia (BPD) 3,765,851 1,807,148 5,572,999
Subtotal, Lung Diseases 143,329,842 64,076,514 207,406,356
Blood Diseases and Resources      
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT)† 6,272,537 243,775 6,516,312
Blood and Marrow Transplant Clinical Research Network 59,071,021 5,319,784 64,390,805
Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial 15,531,903 15,531,903
Transfusion Medicine/Hemostasis Clinical Research Network 57,040,060 6,133,712 63,173,772
Subtotal, Blood Diseases and Resources 137,915,521 11,697,271 149,612,792
Total, NHLBI Cooperative Agreements $856,249,333 $221,647,469 $1,085,548,570

* Formerly known as Targeted Approaches to Weight Control for Young Adults.
** Formerly known as Translating Basic Behavior and Social Science Discoveries Into Interventions to Reduce Obesity.
† Formerly known as Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT (ATTRACT) Trial.

Back to Top

Heart and Vascular Diseases Program

ARIC Neurocognitive Study (ARIC-NCS), Initiated in Fiscal Year 2010

The purpose of this study is to determine whether mid-life vascular risk factors and markers of macrovascular and microvascular disease are predictive of dementia, mild cognitive impairment, and cognitive change in a large biracial ARIC cohort.

Obligations

Funding History:
Fiscal Year 2011—$5,132,469
Fiscal Year 2010—$4,024,211
Total Funding to Date—$9,156,680

Current Active Organizations and Grant Numbers

  1. Johns Hopkins University
    Baltimore, Maryland—HL-096812
  2. University of North Carolina
    Chapel Hill, North Carolina—HL-096814
  3. University of North Carolina
    Chapel Hill, North Carolina—HL-096899
  4. University of Minnesota
    Minneapolis, Minnesota—HL-096902
  5. University of Mississippi Medical Center
    Jackson, Mississippi—HL-096917

Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Cardiovascular Inflammation Reduction Trial, Initiated in Fiscal Year 2011

The purpose of this trial is to test the inflammatory hypothesis of atherothrombosis by evaluating whether low-dose methotrexate will reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among patients with stable CVD who are at increased risk indicated by persistent elevations of high-sensitivity C-reactive protein.

Obligations

Funding History:
Fiscal Year 2011—$1,375,726
Total Funding to Date—$1,375,726

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts—HL-101389
  2. Brigham and Women's Hospital
    Boston, Massachusetts—HL-101422

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether renal artery stenting adds value to optimal medical therapy in terms of cardiovascular and renal outcomes in individuals with a history of resistant hypertension and/or chronic kidney disease and stenosis (>60%) of one or both renal arteries. The trial is in an extended follow-up phase.

Obligations

Funding History:
Fiscal Year 2011—$3,029,201
Fiscal Years 2004–2010—$25,827,224
Total Funding to Date—$28,856,425

Current Active Organizations and Grant Numbers

  1. University of Toledo Health Sciences Campus
    Toledo, Ohio —HL-071556
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota—HL-072734
  3. University of Virginia
    Charlottesville, Virginia—HL-072735
  4. Mid-America Heart Institute of St. Luke Hospital
    Kansas City, Missouri —HL-072736
  5. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-072737

Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillation (CABANA), Initiated in Fiscal Year 2009

The purpose of this trial is to determine whether percutaneous left atrial catheter ablation is superior to current pharmacologic therapy for eliminating atrial fibrillation.

Obligations

Funding History:
Fiscal Year 2011—$3,032,875
Fiscal Years 2009–2010—$5,985,643
Total Funding to Date—$9,018,518

Current Active Organizations and Grant Numbers

  1. Mayo Clinic, College of Medicine
    Rochester, Minnesota —HL-089645
  2. Mayo Clinic, College of Medicine
    Rochester, Minnesota —HL-089709
  3. Duke University
    Durham, North Carolina—HL-089786
  4. Duke University
    Durham, North Carolina—HL-089907

Center for Cardiovascular Outcomes Research, Initiated in Fiscal Year 2010

The purpose of this program is to conduct cardiovascular outcomes research that focuses on patient- and clinician-relevant outcomes of health care and their determinants. The goal is to move clinical evidence into public policy and clinical practice.

Obligations

Funding History:
Fiscal Year 2011—$4,964,931
Fiscal Year 2010—$5,203,594
Total Funding to Date—$10,168,525

Current Active Organizations and Grant Numbers

  1. University of Massachusetts Medical School
    Worcester, Massachusetts —HL-105268
  2. Yale University
    New Haven, Connecticut—HL-105270
  3. Boston Medical Center
    Boston, Massachusetts—HL-105342
  4. Duke University
    Durham, North Carolina—HL-107023

Childhood Obesity Prevention and Treatment Research (COPTR), Initiated in Fiscal Year 2010

See Chapter 11. Clinical Trials.

Claudication: Exercise Versus Endoluminal Revascularization, Initiated in Fiscal Year 2005

The purpose of this study is to optimize physical functioning, increase activity levels, and reduce CVD risk in older individuals with peripheral artery disease. Investigators are determining whether a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with moderate to severe claudication due to aortoiliac insufficiency.

Obligations

Funding History:
Fiscal Year 2011—$1,371,307
Fiscal Years 2005–2010—$7,647,416
Total Funding to Date—$9,018,723

Current Active Organizations and Grant Numbers

  1. Rhode Island Hospital
    Providence, Rhode Island—HL-077221
  2. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-081656

Clinical Research Consortium To Improve Resuscitation Outcomes, Initiated in Fiscal Year 2004

See Chapter 11. Clinical Trials.

Consortium of Hospitals Advancing Research on Tobacco (CHART), Initiated in Fiscal Year 2010

See Chapter 11. Clinical Trials.

Cross Organ Mechanism-Associated Phenotypes for Genetic Analysis of Heart, Lung, Blood, and Sleep Diseases (MAPGen for HLBS) Research Centers, Initiated in Fiscal Year 2011

The purpose of this program is to establish a MAPGen consortium of research centers. The consortium seeks to utilize evolving knowledge of cellular and molecular networks to define common mechanism-associated traits across organ systems. The goal is to redefine disease at the level of pathogenetic mechanisms and phenotype individuals based on pathobiology, rather than clinical presentation. This approach will provide the basis for the development of mechanism-based strategies for prevention, diagnosis, and treatment in individual patients.

Obligations

Funding History:
Fiscal Year 2011—$4,275,465
Total Funding to Date—$4,275,465

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts—HL-108630
  2. University of Southern California
    Los Angeles, California—HL-108634
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-108636
  4. Yale University
    New Haven, Connecticut—HL-108638
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-108642
  6. Stanford University
    Menlo Park, California—HL-108647

Diabetes Prevention Program Outcomes Study—Phase II, Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997

The purpose of this program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is to evaluate patterns of device usage and the immediate and follow-up outcomes in patients who are undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and designing clinical trials to evaluate competing devices. Twenty-four percent of the patients are from various racial and ethnic minority populations.

Obligations

Funding History:
Fiscal Year 2011—$742,170
Fiscal Years 1997–2010—$8,413,711
Total Funding to Date—$9,155,881

Current Active Organization and Grant Number

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-033292

Early Adult Reduction of Weight Through LifestYle Intervention (EARLY) Trials,* Initiated in Fiscal Year 2009

* Formerly known as Targeted Approaches to Weight Control for Young Adults.

See Chapter 11. Clinical Trials.

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000

The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists are seeking to identify and characterize genes that contribute to CVD in this unique and understudied population.

Obligations

Funding History:
Fiscal Year 2011—$51,881
Fiscal Years 2000–2010—$17,504,059
Total Funding to Date—$17,555,940

Current Active Organization and Grant Number

  1. MedStar Research Institute
    Hyattsville, Maryland —HL-064244

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

ISCHEMIA Trial (International Study of Comparative Effectiveness With Medical Invasive Approaches), Initiated in Fiscal Year 2011

The purpose of this trial is to define the role of an invasive approach in patients with stable ischemic heart disease and substantial ischemia. Investigators will determine whether cardiac catheterization followed by complete revascularization plus optimal medical therapy is superior to optimal medical therapy alone as the management strategy for patients with moderate-severe ischemia on stress imaging. Cost-effectiveness will also be assessed.

Obligations

Funding History:
Fiscal Year 2011—$6,671,629
Total Funding to Date—$6,671,629

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina—HL-105462
  2. Emory University
    Atlanta, Georgia—HL-105561
  3. Duke University
    Durham, North Carolina—HL-105565
  4. New York University School of Medicine
    New York, New York—HL-105907

Look AHEAD: Action for Health in Diabetes, Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Next Generation Genetic Association Studies, Initiated in Fiscal Year 2011

The purpose of this study is to investigate functional aspects of genetic variation in humans by combining cellular reprogramming strategies with molecular profiling or cellular assays, and then integrating the information with existing genotypic and clinical phenotypic data to assess how naturally occurring human genetic variation influences the activities of biological networks in cell-based models of disease. Researchers are seeking to develop the technology needed for high-throughput iPS cell line generation and differentiation and will use the technology to follow up on genomic associations with additional mechanistic information gained from cellular models of disease.

Obligations

Funding History:
Fiscal Year 2011—$5,855,804
Total Funding to Date—$5,855,804

Current Active Organizations and Grant Numbers

  1. Stanford University
    Stanford, California—HL-107388
  2. Stanford University
    Stanford, California —HL-107393
  3. Scripps Research Institute
    La Jolla, California—HL-107436
  4. Medical College of Wisconsin
    Milwaukee, Wisconsin —HL-107437
  5. Massachusetts General Hospital
    Boston, Massachusetts —HL-107440
  6. University of California, San Diego
    La Jolla, California—HL-107442
  7. Boston University Medical Campus
    Boston, Massachusetts—HL-107443
  8. Johns Hopkins University
    Baltimore, Maryland —HL-107446
  9. University of Pennsylvania
    Philadelphia, Pennsylvania —HG-006398

NHLBI Cardiac Development Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to elucidate the regulatory networks controlling cardiovascular development. A consortium of multidisciplinary research teams will select key regulatory pathways, identify components of the pathways and targets, and disseminate data to the scientific community. Research results may lead to the development of regenerative therapies and tissue engineering approaches.

Obligations

Funding History:
Fiscal Year 2011—$7,037,111
Fiscal Years 2009–2010—$8,239,641
Total Funding to Date—$15,276,752

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah —HL-098160
  2. Harvard University Medical School
    Boston, Massachusetts—HL-098166
  3. J. David Gladstone Institutes
    San Francisco, California—HL-098179
  4. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-098180

NHLBI Pediatric Cardiac Genomics Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to conduct clinical and translational research on the genetic causes of congenital heart disease and the genetic contributions to outcomes in individuals with congenital heart disease.

Obligations

Funding History:
Fiscal Year 2011—$3,814,314
Fiscal Years 2009–2010—$5,143,441
Total Funding to Date—$8,957,755

Current Active Organizations and Grant Numbers

  1. Mount Sinai School of Medicine
    New York, New York—HL-098123
  2. Children's Hospital Boston
    Boston, Massachusetts—HL-098147
  3. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-098153
  4. Yale University
    New Haven, Connecticut—HL-098162
  5. Columbia University Health Sciences
    New York, New York—HL-098163

NHLBI Pediatric Translational Consortium Administrative Coordinating Center, Initiated in Fiscal Year 2009

The purpose of this Coordinating Center is to provide administrative support for the Cardiovascular Development Consortium and the Pediatric Cardiac Genomics Consortium, monitor multicenter patient recruitment by the Pediatric Cardiac Genomics Consortium, and administer funds to consortium-wide cores.

Obligations

Funding History:
Fiscal Year 2011—$0
Fiscal Years 2009–2010—$10,453,976
Total Funding to Date—$10,453,976

Current Active Organization and Grant Number

  1. New England Research Institute, Inc.
    Watertown, Massachusetts—HL-98188

NHLBI Progenitor Cell Biology Consortium Research Hubs, Initiated in Fiscal Year 2009

The purpose of this study is to establish virtual research hubs that focus on progenitor cell biology. Investigators are seeking to identify and characterize progenitor cell lineages, direct the differentiation of stem and progenitor cells to desired cell fates, and develop new strategies to address the unique challenges presented by the transplantation of progenitor cells.

Obligations

Funding History:
Fiscal Year 2011—$22,514,886
Fiscal Years 2009–2010—$46,788,094
Total Funding to Date—$69,302,980

Current Active Organizations and Grant Numbers

  1. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-099656
  2. University of Wisconsin, Madison
    Madison, Wisconsin —HL-099773
  3. Johns Hopkins University
    Baltimore, Maryland—HL-099775
  4. Stanford University
    Stanford, California —HL-099776
  5. Fred Hutchinson Cancer Research Center
    Seattle, Washington—HL-099993
  6. Stanford University
    Stanford, California —HL-099995
  7. University of Maryland
    Baltimore, Maryland—HL-099997
  8. Stanford University
    Stanford, California —HL-099999
  9. Children's Hospital Boston
    Boston, Massachusetts—HL-100001
  10. Fred Hutchinson Cancer Research Center
    Seattle, Washington—HL-100395
  11. Stanford University
    Stanford, California —HL-100397
  12. Vanderbilt University
    Nashville, Tennessee—HL-100398
  13. University of Texas Southwestern Medical Center
    Dallas, Texas—HL-100401
  14. Massachusetts General Hospital
    Boston, Massachusetts—HL-100402
  15. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-100405
  16. J. David Gladstone Institutes
    San Francisco, California—HL-100406
  17. University of Minnesota, Twin Cities
    Minneapolis, Minnesota—HL-100407
  18. Massachusetts General Hospital
    Boston, Massachusetts—HL-100408

Obesity Related Behavioral Intervention Trials (ORBIT),* Initiated in Fiscal Year 2009

* Formerly known as Translating Basic Behavioral and Social Sciences Discoveries Into Interventions To Reduce Obesity.

The purpose of this study is to translate findings from basic research on human behavior into more effective clinical, community, and population interventions to reduce obesity and improve obesity-related behaviors. Investigators are seeking to develop innovative obesity-reducing strategies that are effective in small-scale trials, acceptable to target populations of interest and are ready for testing in large-scale randomized clinical and community trials. Some of the projects are expected to have 50–100 percent participation from minority populations.

Obligations

Funding History:
Fiscal Year 2011—$4,297,228
Fiscal Years 2009–2010—$10,987,451
Total Funding to Date—$15,284,679

Current Active Organizations and Grant Numbers

  1. Claremont Graduate University
    Claremont, California —HL-097839
  2. 2. Weill Medical College of Cornell University
    New York, New York—HL-097843
  3. Wayne State University
    Detroit, Michigan—HL-097889
  4. Rush University Medical Center
    Chicago, Illinois—HL-097894
  5. University of California, San Francisco
    San Francisco, California—HL-097973

Pediatric Heart Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this program is to establish a network of multidisciplinary, collaborative research groups to study how genetic variation contributes to interindividual differences in responses to medications. Four studies under this initiative are investigating the pharmacogenetics of heart, lung, and blood diseases. One of the projects has 38 percent minority participation. The Pharmacogenetics Knowledgebase (PharmGKB) has been established to integrate information obtained from pharmacogonomics, phenotypes, and genotypes.

Obligations

Funding History:
Fiscal Year 2011—$6,532,424
Fiscal Years 2001–2010—$74,421,366
Total Funding to Date—$80,953,760

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital and Harvard Medical School
    Boston, Massachusetts—HL-065899
  2. Vanderbilt University
    Nashville, Tennessee—HL-065962
  3. Children's Hospital and Research Center
    Oakland, California—HL-069757
  4. University of Maryland
    Baltimore, Maryland—HL-105198

Ranolazine in Implantable Defibrillators (RAID) Trial, Initiated in Fiscal Year 2010

The purpose of this clinical trial is to determine whether ranolazine will reduce the risk of ventricular arrhythmias and improve survival in high-risk patients who already have an implantable cardiac defibrillator. Currently, very few options are available for treating patients at risk for ventricular arrhythmias—which often leads to death—and ranolazine may be a safe and effective treatment.

Obligations

Funding History:
Fiscal Year 2011—$0
Fiscal Year 2010—$2,279,794
Total Funding to Date—$2,279,794

Current Active Organizations and Grant Numbers

  1. University of Rochester
    Rochester, New York—HL-096607
  2. University of Rochester
    Rochester, New York—HL-096610

Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II), Initiated in Fiscal Year 2009

The purpose of this study is to determine whether using cardiac computed assisted tomography early in the emergency department triage will enable immediate and safe discharge without further testing of a significant number of patients with acute chest pain.

Obligations

Funding History:
Fiscal Year 2011—$366,525
Fiscal Years 2009–2010—$4,419,188
Total Funding to Date—$4,785,713

Current Active Organizations and Grant Numbers

  1. Massachusetts General Hospital
    Boston, Massachusetts—HL-092022
  2. Massachusetts General Hospital
    Boston, Massachusetts—HL-092040

Strong Heart Study, Initiated in Fiscal Year 1988

The objectives of this study are to survey CVD morbidity and mortality rates among three geographically diverse groups of American Indians and estimate their levels of CVD risk factors. Phases II and III of the cohort study extended surveillance of community mortality and assessed development of CVD and changes in CVD risk factors. In Phase III, investigators added a substudy of asthma and a pilot family study. Phase IV expanded the family study to 120 families comprising 3,600 members to investigate genetic and environmental contributors of CVD. Phase V examined the family study cohort to assess genetic relationships to risk factor change over a 5‑year period and initiated surveillance for cardiovascular morbidity and mortality.

Obligations

Funding History:
Fiscal Year 2011—$2,144,794
Fiscal Years 1988–2010—$73,879,041
Total Funding to Date—$76,023,835

Current Active Organizations and Grant Numbers

  1. Medstar Research Institute
    Hyattsville, Maryland—HL-041642
  2. Missouri Breaks Research, Inc.
    Timberlake, South Dakota —HL-041652
  3. University of Oklahoma
    Oklahoma City, Oklahoma—HL-041654
  4. Weill Medical College of Cornell University
    New York, New York—HL-065521

Surgical Treatment for Ischemic Heart Failure (STICH), Initiated in Fiscal Year 2002

The objective of this clinical trial is to continue to follow for 5 more years, patients who were assigned to the first part of the STICH study that sought to determine whether the addition of CABG to intensive medical therapy improves long-term survival of patients with heart failure and left ventricular dysfunction. The original study found no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary endpoint of death from any cause. However, the secondary endpoint related to deaths due to cardiovascular causes showed that patients assigned to CABG had lower rates of death compared with those assigned to medical therapy alone.

The extension study (STICHES) will enable investigators to obtain long-term (10-year average) data on survivors from the original cohort. The primary endpoint is all-cause mortality. Secondary endpoints include cardiovascular mortality; cardiovascular morbidity defined by hospitalization for heart failure, myocardial infarction, or need for coronary revascularization procedure; and functional status and symptoms. Approximately 25 percent of the population will come from minority populations.

Obligations

Funding History:
Fiscal Year 2011—$352,198
Fiscal Years 2002–2010—$40,041,062
Total Funding to Date—$40,393,260

Current Active Organization and Grant Number

  1. Duke University
    Durham, North Carolina—HL-069015

Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials, Initiated in Fiscal Year 2009

The purpose of this program is to determine whether therapeutic hypothermia after pediatric cardiac arrest improves outcomes, including survival, in infants and children. Approximately 50 percent of the patients are expected to come from racial and ethnic minority populations.

Obligations

Funding History:
Fiscal Year 2011—$4,401,772
Fiscal Years 2009–2010—$5,993,723
Total Funding to Date—$10,395,495

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah —HL-094339
  2. University of Michigan at Ann Arbor
    Ann Arbor, Michigan—HL-094345

Lung Diseases Program

Asthma Networks (AsthmaNet), Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

COPD Clinical Research Network, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT), Initiated in Fiscal Year 2011

The purpose of this study is to determine whether safe and effective tight glycemic control can sufficiently reduce morbidity and mortality in children with heart and lung failure to justify a low risk of hypoglycemia.

Obligations

Funding History:
Fiscal Year 2011—$2,685,460
Total Funding to Date—$2,685,460

Current Active Organizations and Grant Numbers

  1. Children's Hospital Boston
    Boston, Massachusetts—HL-107681
  2. Children's Hospital Boston
    Boston, Massachusetts—HL-108028

Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), Initiated in Fiscal Year 2008

The purpose of this randomized clinical trial is to assess the efficacy and safety of 7 percent hypertonic saline inhaled twice daily for 48 weeks among infants with CF aged 4 to 15 months at enrollment. Investigators are seeking to determine whether hypertonic saline will improve hyperinflation and obstructive lung disease as measured by infant lung function testing compared with the control agent (isotonic saline).

Obligations

Funding History:
Fiscal Year 2011—$628,241
Fiscal Years 2008–2010—$2,224,874
Total Funding to Date—$2,873,115

Current Active Organizations and Grant Numbers

  1. Children's Hospital and Regional Medical Center
    Seattle, Washington—HL-092931
  2. University of Washington
    Seattle, Washington—HL-092932

Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls, Initiated in Fiscal Year 2009

The purpose of this study is to characterize the microbiome of the lung alone or in combination with the upper airways in HIV-infected individuals and matched HIV-uninfected controls. Investigators will use molecular techniques to identify bacteria, and if possible, other organisms (e.g., viruses, cell-wall deficient organisms, protozoa, and fungi). Data will be used to examine the effects of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, HIV-related respiratory complications, and anti-HIV therapies.

Obligations

Funding History:
Fiscal Year 2011—$5,324,656
Fiscal Years 2009–2010—$10,743,005
Total Funding to Date—$16,067,661

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-098957
  2. George Washington University
    Washington, DC—HL-098958
  3. Indiana University-Purdue University, Indianapolis
    Indianapolis, Indiana—HL-098960
  4. University of Michigan, Ann Arbor
    Ann Arbor, Michigan—HL-098961
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-098962
  6. University of California, San Francisco
    San Francisco, California—HL-098964
  7. University of Colorado
    Denver, Colorado—HL-098966

Novel Therapies for Lung Diseases—Phase II, Initiated in Fiscal Year 2010

See Chapter 11. Clinical Trials.

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment.

Obligations

Funding History:
Fiscal Year 2011—$1,957,381
Fiscal Years 2000–2010— $28,998,338
Total Funding to Date—$30,955,719

Current Active Organization and Grant Number

  1. Brigham and Women's Hospital
    Boston, Massachusetts—HL-065899

Prematurity and Respiratory Outcomes Program (PROP), Initiated in Fiscal Year 2010

The purpose of this observational clinical study is to investigate hypotheses on the molecular mechanisms that contribute to respiratory disease risk of the premature newborn with the long-term goal of improving outcomes in the first year of life.

Obligations

Funding History:
Fiscal Year 2011—$4,066,948
Fiscal Year 2010—$1,597,280
Total Funding to Date—$5,664,228

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee—HL-101456
  2. Washington University
    St. Louis, Missouri —HL-101465
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-101794
  4. University of California, San Francisco
    San Francisco, California —HL-101798
  5. Children's Hospital Medical Center, Cincinnati
    Cincinnati, Ohio—HL-101800
  6. University of Rochester
    Rochester, New York—HL-101813

Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk, Initiated in Fiscal Year 2010

The purpose of this study is to create a network of clinical research sites with a Data Coordinating and Analysis Center to develop common research protocols to study the cardiovascular health of women in their first pregnancy and assess the significance of disordered breathing.

Obligations

Funding History:
Fiscal Year 2011—$3,298,000
Fiscal Year 2010—$500,000
Total Funding to Date—$3,798,000

Current Active Organization and Grant Number

  1. Research Triangle Institute
    Research Triangle, North Carolina—HD-063036

Randomized Trial of Antenatal Late Preterm Steroids (ALPS), Initiated in Fiscal Year 2010

The purpose of this study is to determine whether antenatal corticosteroids can potentially improve lung function and reduce respiratory morbidity in newborn infants who are born in the late preterm period (34–36 weeks). Previous studies have shown that steroids improve lung function in very premature infants. Fifty-five percent of the participants are expected to come from racial and ethnic minority populations.

Obligations

Funding History:
Fiscal Year 2011—$2,137,414
Fiscal Year 2010—$2,133,947
Total Funding to Date—$4,271,361

Current Active Organizations and Grant Numbers

  1. George Washington University
    Washington, DC—HL-098354
  2. Columbia University Health Sciences
    New York, New York—HL-098554

Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma, Initiated in Fiscal Year 2009

The purpose of this randomized clinical trial is to determine whether supplemental vitamin D to increase the level of vitamin D in a pregnant woman will prevent asthma and allergy in her child at age 3 years. Investigators will recruit 870 pregnant women who are in the first trimester of pregnancy and randomize them to one of two treatment arms of a 4-year clinical trial: one arm being treatment with 4,000 international units of vitamin D in addition to typical prenatal vitamins and the other being treatment with typical prenatal vitamins alone. Currently, 80 percent of the participants are from racial and ethnic minority populations.

Obligations

Funding History:
Fiscal Year 2011—$2,469,339
Fiscal Years 2009–2010—$4,975,916
Total Funding to Date—$7,445,255

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-091075
  2. Brigham and Women's Hospital
    Boston, Massachusetts—HL-091528

Sedation Management in Pediatric Patients With Acute Respiratory Failure, Initiated in Fiscal Year 2008

The purpose of this randomized clinical trial is to test an innovative approach to sedation management that includes team education and consensus on the use of sedatives in pediatric patients supported on mechanical ventilation; team identification of each patient's trajectory of illness and daily prescription of a sedation goal; use of a nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines; and team feedback on sedation management performance. Investigators have randomized 2,754 critically ill infants and children into two study groups: sedation management intervention and usual care. Forty-five percent of the patients are from racial and ethnic minority populations.

Obligations

Funding History:
Fiscal Year 2011—$2,181,199
Fiscal Years 2008–2010—$7,779,116
Total Funding to Date—$9,960,315

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-086622
  2. Children's Hospital Boston
    Boston, Massachusetts—HL-086649

Severe Asthma Research Program,* Initiated in Fiscal Year 2011

* The Severe Asthma Research Program began in FY 2001 and was funded under the R01 mechanism.

The purpose of this study is to define severe asthma at the molecular and cellular levels longitudinally to understand its evolution. Research findings will serve as a rational basis for designing mechanism-based diagnostic, prognostic, and treatment strategies for severe asthma.

Obligations

Funding History:
Fiscal Year 2011—$5,159,933
Total Funding to Date—$5,159,933

Current Active Organizations and Grant Numbers

  1. Pennsylvania State University, Hershey Medical Center
    Hershey, Pennsylvania—HL-109086
  2. University of California, San Francisco
    San Francisco, California —HL-109146
  3. University of Pittsburgh, Pittsburgh
    Pittsburgh, Pennsylvania —HL-109152
  4. Wake Forest University Health Sciences
    Winston-Salem, North Carolina —HL-109164
  5. University of Wisconsin, Madison
    Madison, Wisconsin—HL-109168
  6. Brigham and Women's Hospital
    Boston, Massachusetts —HL-109172
  7. University of Virginia, Charlottesville
    Charlottesville, Virginia —HL-109250
  8. Washington University
    St. Louis, Missouri—HL-109257

Study of Asthma and Nasal Steroids (STAN), Initiated in Fiscal Year 2009

The purpose of this clinical trial is to determine whether treatment of chronic rhinitis and sinusitis with a nasal steroid improves asthma control. Investigators have randomized 380 patients with poorly controlled asthma and chronic rhinitis and sinusitis to a nasal steroid or matching placebo in addition to their regular asthma treatment. One third of participants are expected to be from minority populations.

Obligations

Funding History:
Fiscal Year 2011—$724,884
Fiscal Years 2009–2010—$1,449,536
Total Funding to Date—$2,174,420

Current Active Organizations and Grant Numbers

  1. University of Vermont
    Burlington, Vermont —HL-089464
  2. Johns Hopkins University
    Baltimore, Maryland—HL-089510

Study of Soy Isoflavones in Asthma (SOYA), Initiated in Fiscal Year 2009

The purpose of this double-blind, randomized con­trolled trial is to determine whether genistein supplements (soy isoflavone) improves lung func­tion in patients with poorly controlled asthma. The study includes 380 patients with low dietary soy intake, ages 12 years and older, who are taking either inhaled corticosteroids or leukotriene modifiers or both and have poorly controlled asthma. Participants are being randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein, and glycitein) 100 mg daily or to placebo for 6 months. Thirty percent of participants are expected to be from minority populations.

Obligations

Funding History:
Fiscal Year 2011—$688,673
Fiscal Years 2009–2010—$1,417,854
Total Funding to Date—$2,106,527

Current Active Organizations and Grant Numbers

  1. Northwestern University
    Evanston, Illinois—HL-087987
  2. Johns Hopkins University
    Baltimore, Maryland—HL-088367

Trial of Late Surfactant (TOLSURF) To Prevent Bronchopulmonary Dysplasia, Initiated in Fiscal Year 2009

The purpose of this randomized controlled clinical trial is to determine whether late doses of surfactant in addition to iNO administered to extremely low gestational age neonates (< 30 weeks) who require mechanical ventilation between 7 and 14 days of age will increase survival without bronchopulmonary dysplasia.

Obligations

Funding History:
Fiscal Year 2011—$1,807,148
Fiscal Years 2009–2010—$3,765,851
Total Funding to Date—$5,572,999

Current Active Organizations and Grant Numbers

  1. University of California, San Francisco
    San Francisco, California—HL-094338
  2. University of California, San Francisco
    San Francisco, California—HL-094355

Blood Diseases and Resources

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT),* Initiated in Fiscal Year 2008

* Formerly known as Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT (ATTRACT) Trial.

The purpose of this study is to determine whether adjunctive pharmacomechanical catheter-directed thrombolysis (PCDT), which includes intrathrombus admin­­istration of recombinant tissue plasminogen activator, can prevent postthrombotic syndrome in patients with symptomatic proximal deep vein thrombosis (DVT). Investigators are comparing the addition of PCDT to optimal standard DVT therapy with optimal standard DVT therapy alone.

Obligations

Funding History:
Fiscal Year 2011—$243,775
Fiscal Years 2008–2010—$6,272,537
Total Funding to Date—$6,516,312

Current Active Organizations and Grant Numbers

  1. McMaster University
    Hamilton, Ontario —HL-088118
  2. Washington University
    St. Louis, Missouri —HL-088476

Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial, Initiated in Fiscal Year 2008

The purpose of this study is to determine the safety and efficacy of low molecular weight heparin (LMWH) in adults with atrial fibrillation who stop warfarin in preparation for surgery. The trial randomly allocated 3,282 patients with atrial fibrillation to either LMWH or placebo before and after surgery. Investigators hypothesize that simply withholding warfarin in a perioperative setting for patients with atrial fibrillation will not meaningfully increase the risk for arterial thromboembolism and will forestall hemorrhagic complications, compared with a strategy using LMWH before and after surgery. One-third of participants are expected to be from minority populations.

Obligations

Funding History:
Fiscal Year 2011—$0
Fiscal Years 2008–2010—$15,531,903
Total Funding to Date—$15,531,903

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina—HL-086755
  2. Duke University
    Durham, North Carolina—HL-087229

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

See Chapter 11. Clinical Trials.

NHLBI Centers of Research Program (P50)

The Centers of Research Program supports specialized centers that focus on multidisciplinary research and development from basic science to clinical investigation in response to announcements of the programmatic needs of the Institute. The spectrum of activities comprises a multifaceted attack on a specific disease entity or biomedical problem area.

NHLBI Centers of Research Program

Obligations (Dollars in Thousands)

Type of Center Period of Operation Prior to
FY 2011
FY 2011 Total to Date
NIH Centers for Population and Health Disparities (CPHHD) 2010– $9,898 $10,169 $20,067
Subtotal, CPHHD   $9,898 $10,169 $20,067
Specialized Centers of Clinically Oriented Research (P50)        
Heart and Vascular Diseases Program        
Vascular Injury, Repair, and Remodeling 2006– 69,643 1,760 71,403
Subtotal, Heart and Vascular Diseases Program   69,643 1,760 71,403
Lung Diseases Program        
Chronic Obstructive Pulmonary Disease 2007– 44,781 8,775 53,556
Pulmonary Vascular Disease 2007– 25,558 4,660 30,218
Subtotal, Lung Diseases Program   70,339 13,435 83,774
Subtotal, SCCOR (P50)   $139,982 $15,195 $155,177
Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) 2011 $9,000 $9,000
Subtotal, CADET   $9,000 $9,000
Total, Centers of Research Program (P50)   $149,880 $34,364 $184,244

NIH Centers for Population Health and Health Disparities (CPHHD) (P50)

The purpose of this program is to create centers of transdisciplinary research that will evaluate the multilevel determinants of health disparities and devise interventions to reduce them.

Obligations

Fiscal Year 2011—$10,168,814

Current Active Organizations and Grant Numbers

  1. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina—HL-105184
  2. Northeastern University
    Boston, Massachusetts—HL-105185
  3. Johns Hopkins University
    Baltimore, Maryland—HL-105187
  4. University of California, Los Angeles
    Los Angeles, California—HL-105188
  5. Rush University Medical Center
    Chicago, Illinois—HL-105189

Specialized Centers of Clinically Oriented Research (P50)

The NHLBI initiated the Specialized Centers of Research (SCOR) program in 1971 to encourage translational research—converting basic science findings to the clinic—in high priority areas. The SCOR concept emphasized multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In FY 2002, the NHLBI revised its SCOR program—primarily on recommendation from the NHLBAC—to place more emphasis on clinical research projects. The SCCOR program still requires clinical and basic scientists to work together on a unified theme, but also requires at least 50 percent of the projects to be clinical. The SCOR program ended in FY 2008.

A description of the SCCORs supported by the Institute follows.

Heart Diseases Program

Vascular Injury, Repair, and Remodeling

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions that will enable basic science findings to be more rapidly translated into clinical applications. Major goals of the program are to stimulate interdependent clinical and multidisciplinary basic research projects that investigate molecular and cellular mechanisms of vascular injury, repair, and remodeling; promote patient-oriented research that will improve our ability to prevent, detect, characterize, manage, and treat vascular diseases; and develop the skills and research capabilities of new clinical investigators.

Obligations

Fiscal Year 2011—$1,759,969

Current Active Organization and Grant Number

  1. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-083813

Lung Diseases Program

Chronic Obstructive Pulmonary Disease

The purpose of this SCCOR is to foster multidisciplinary research to accelerate progress in the diagnosis, prevention, and treatment of COPD. The program includes a broad spectrum of basic and clinical research that encompasses animal models of COPD pathogenesis; human proteomic, genetic, and genomic investigations; disease phenotypes classification; and the development of new therapeutic interventions.

Obligations

Fiscal Year 2011—$8,775,106

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-084922
  2. Weill Medical College of Cornell University
    New York, New York—HL-084936
  3. Johns Hopkins University
    Baltimore, Maryland—HL-084945
  4. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-084948

Pulmonary Vascular Disease

The objective of this SCCOR is to facilitate multidisciplinary research that proposes original hypotheses and applies cutting-edge approaches, including genomics and proteomics, to clinical issues in pulmonary vascular disease.

Obligations

Fiscal Year 2011—$4,660,206

Current Active Organizations and Grant Numbers

  1. University of Colorado, Denver
    Denver, Colorado—HL-084923
  2. Johns Hopkins University
    Baltimore, Maryland —HL-084946

Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) (P50)

The purpose of this program is to accelerate the development of novel agents for the diagnosis and treatment of lung diseases and sleep disordered breathing through the use of rational strategies based on fundamental pathobiologic processes. CADET I provides opportunities to explore potential targets for validation to determine which are amenable for development of mechanism-based modalities for direct clinical application in the prevention, diagnosis, and treatment of pulmonary diseases and sleep disordered breathing.

Obligations

Fiscal Year 2011—$9,000,370

Current Active Organizations and Grant Numbers

  1. Children's Hospital Medical Center Cincinnati
    Cincinnati, Ohio—HL-107159
  2. University of Chicago
    Chicago, Illinois—HL-107160
  3. Brigham and Women's Hospital
    Boston, Massachusetts—HL-107165
  4. Brigham and Women's Hospital
    Boston, Massachusetts—HL-107166
  5. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina—HL-107168
  6. Johns Hopkins University
    Baltimore, Maryland—HL-107169
  7. University of Chicago
    Chicago, Illinois—HL-107171
  8. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-107172
  9. University of Michigan, Ann Arbor
    Ann Arbor, Michigan—HL-107177
  10. Duke University
    Durham, North Carolina—HL-107180
  11. University of Alabama, Birmingham
    Birmingham, Alabama—HL-107181
  12. Johns Hopkins University
    Baltimore, Maryland—HL-107182
  13. Washington University
    Saint Louis, Missouri—HL-107183
  14. Johns Hopkins University
    Baltimore, Maryland—HL-107185
  15. University of Texas Health Center at Tyler
    Tyler, Texas—HL-107186
  16. University of Arizona
    Tucson, Arizona—HL-107188
  17. Johns Hopkins University
    Baltimore, Maryland—HL-107190
  18. University of California, San Francisco
    San Francisco, California—HL-107191
  19. Brigham and Women's Hospital
    Boston, Massachusetts—HL-107192

Basic and Translational Research Program (U54)

The NHLBI reconfigured the Comprehensive Sickle Cell Centers program into a Basic and Translational Research Program (BTRP). The Program emphasizes fundamental investigations and their translation into initial studies in humans, as well as community translation to promote evidence-based clinical practice. The BTRP continues to support the Sickle Cell Disease Scholars program for the career development of young investigators and the Summer-for-Sickle Cell-Science program for research training and mentoring of high-school students. These components are part of a larger effort by the NHLBI to prepare the next generation of scientists to advance the field of SCD research.

Obligation

Fiscal Year 2011—$5,901,312

Current Active Organizations and Grant Numbers

  1. Thomas Jefferson University
    Philadelphia, Pennsylvania —HL-070585
  2. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina —HL-070587
  3. University of Texas, Southwest Medical Center
    Dallas, Texas—HL-070588
  4. St. Jude's Children's Research Hospital
    Memphis, Tennessee —HL-070590
  5. Boston Medical Center
    Boston, Massachusetts—HL-070819
  6. Children's Hospital Medical Center
    Cincinnati, Ohio—HL-070871
  7. Medical College of Wisconsin
    Milwaukee, Wisconsin—HL-090503
  8. Howard University
    Washington, DC—HL-090508
  9. Children's Hospital of Los Angeles
    Los Angeles, California—HL-090511
  10. University of Illinois, at Chicago
    Chicago, Illinois—HL-090513
  11. Johns Hopkins University
    Baltimore, Maryland—HL-090515
  12. Virginia Commonwealth University
    Richmond, Virginia—HL-090516
  13. University of Miami, School of Medicine
    Coral Gables, Florida—HL-090569

Cardiac Translational Research Implementation Program (C-TRIP) (P20)

The C-TRIP program was initiated in FY 2010 to accelerate the translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias. The program consists of two stages. Stage 1 focuses on planning and developing clinical trials to determine the safety and efficacy of interventions to be conducted during Stage 2 of the overall program. Stage 2 studies will be supported by the P50 mechanism.

Obligation

Fiscal Year 2011—$8,592,776

Current Active Organizations and Grant Numbers

  1. Mount Sinai School of Medicine
    New York, New York —HL-100396
  2. Johns Hopkins University
    Baltimore, Maryland —HL-101397
  3. Brigham and Women's Hospital
    Boston, Massachusetts —HL-101408
  4. University of Medicine and Dentistry of New Jersey
    New Jersey Medical School
    Newark, New Jersey —HL-101420
  5. Vanderbilt University
    Nashville, Tennessee —HL-101425
  6. University of Maryland, Baltimore
    Baltimore, Maryland —HL-101434
  7. University of Colorado, Denver
    Aurora, Colorado —HL-101435
  8. Texas Heart Institute
    Houston, Texas —HL-101438
  9. Mayo Clinic
    Rochester, Minnesota —HL-101439
  10. University of Miami School of Medicine
    Miami, Florida — HL-101443
  11. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-101820
  12. Brigham and Women's Hospital
    Boston, Massachusetts—HL-101866

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

Fiscal Year 2011—$3,333,747

Current Active Organizations and Grant Numbers

  1. University of Washington
    Seattle, Washington—AI-027757
  2. University of California, San Francisco
    San Francisco, California —AI-027763
  3. University of Alabama, Birmingham
    Birmingham, Alabama—AI-027767
  4. University of California, Los Angeles
    Los Angeles, California—AI-028697
  5. Baylor University
    Houston, Texas —AI-036211
  6. University of California, La Jolla
    La Jolla, California—AI-036214
  7. Case Western Reserve University
    Cleveland, Ohio —AI-036219
  8. University of Massachusetts, Worcester
    Worcester, Massachusetts—AI-042845
  9. Miriam Hospital
    Providence, Rhode Island —AI-042853
  10. University of Pennsylvania
    Philadelphia, Pennsylvania—AI-045008
  11. Emory University
    Atlanta, Georgia—AI-050409
  12. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina—AI-050410
  13. Yeshiva University
    New York, New York —AI-051519
  14. Vanderbilt University
    Nashville, Tennessee—AI-054999
  15. Harvard Medical School
    Boston, Massachusetts—AI-060354
  16. Duke University
    Durham, North Carolina —AI-064518
  17. University of Miami School of Medicine
    Coral Gables, Florida —AI-073961
  18. University of Rochester
    Rochester, New York —AI-078498
  19. Rush University Medical Center
    Chicago, Illinois —AI-082151
  20. George Washington University
    Washington, DC—AI-087714

Back to Top

« Fact Book Table of Contents

Skip footer links and go to content
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon